CD8A and non-small cell lung carcinoma: Inspiringly, intervention of KRT19 in NSCLC cells enhanced anti-PD-1 immunotherapy efficiency by potentiating stronger antineoplastic responses of tumor-infiltrating cytotoxic CD8+ T cells (CTLs).